The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Investigating novel therapeutic approaches for T-cell lymphoma
In this video, Yumeng Zhang, MD, Moffitt Cancer Center, Tampa, FL, briefly discusses novel therapies under investigation for T-cell lymphoma, emphasizing the need for effective, well-tolerated treatments. She mentions ropeginterferon alfa-2b, an interferon-based therapy currently under investigation in a Phase I/Ib trial (NCT07047885) in cutaneous T-cell lymphoma (CTCL). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In T-cell lymphoma, there are a couple of things that are coming out. It’s very exciting as we know a little bit more and more about the immunology behind T-cell lymphoma. I treat cutaneous T-cell lymphoma mostly. So as you know, it’s an incurable cancer. And we desperately need therapy that’s effective as well as very tolerable. So right now, we actually have a clinical trial to look at interferon-based therapy with a new therapy called ropeginterferon to see its efficacy in T-cell lymphoma...
In T-cell lymphoma, there are a couple of things that are coming out. It’s very exciting as we know a little bit more and more about the immunology behind T-cell lymphoma. I treat cutaneous T-cell lymphoma mostly. So as you know, it’s an incurable cancer. And we desperately need therapy that’s effective as well as very tolerable. So right now, we actually have a clinical trial to look at interferon-based therapy with a new therapy called ropeginterferon to see its efficacy in T-cell lymphoma. And there are other therapies that we’re looking into, like immune checkpoint inhibitor immunotherapy, to try to get those patients to a point where they don’t have to worry about their disease and live their normal life. Also, don’t worry about the toxicity of the drugs.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
